Dobutamine
As of the edition of 20 October 2026, Dobutamine is a small molecule: marketed, first approved in 1982 (US); acts on ADRB1 and ADRB2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Dobutrex
- First approved
- 1 January 1982 (US)
- Approvals on record
- 14 in 3 regions
- Holder of the most recent approval
- SUN PHARMACEUTICAL INDUSTRIES EUROPE (PAYS BAS); 5 holders in all
- Registered trials
- 45, 4 stopped early
- Disease areas
- Heart and blood vessels; Infections; Inherited and neonatal; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Dobutamine.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 18 | 13 | 1 | 0 |
| Phase 1 | 4 | 1 | 0 | 1 |
| Phase 2 | 11 | 3 | 3 | 3 |
| Phase 3 | 5 | 3 | 0 | 0 |
| Phase 4 | 7 | 3 | 0 | 0 |
| All trials | 45 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Abbott | Later holder and Lead sponsor of trials | 1993 to now |
| Baxter Healthcare | Later holder | 1993 to now |
| Pfizer | Acquired holder | 2005 to now |
| Eli Lilly | Applicant |